du.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • chicago-author-date
  • chicago-note-bibliography
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Circulating plasma levels of cathepsin S and L are not associated with disease severity in patients with rheumatoid arthritis
Department of Surgery, Umeå University, Umeå, Sweden.
Department of Public Health and Clinical Medicine/Rheumatology, Umeå University Hospital, Umeå, Sweden.
e/Rheumatology, Umeå University Hospital, Umeå, Sweden.
Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden.
Visa övriga samt affilieringar
2014 (Engelska)Ingår i: Scandinavian Journal of Rheumatology, ISSN 0300-9742, E-ISSN 1502-7732, Vol. 43, nr 2, s. 371-373Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Background: Rheumatoid arthritis (RA) is characterized by chronic synovitis and articular cartilage destruction. Increased activities of cathepsin S and cathepsin L, two potent cysteine proteases, are thought to play a role in the pathogenesis of the irreversible articular cartilage destruction. Nevertheless, data regarding the potential importance of the cathepsins as circulating biomarkers in RA patients are limited.

Method: Subjects enrolled in this study are part of a larger study where patients from the three northern counties of Sweden diagnosed with early RA are followed in an ongoing prospective study. In total, 71 patients were included, along with 44 age- and sex-matched control subjects. Plasma levels of cathepsin S and L were analysed. Disease severity was assessed using the 28-joint count Disease Activity Score (DAS28).

Results: Plasma levels of cathepsin S and L were significantly increased in patients with RA compared to healthy controls (p < 0.05 for both). However, in the patients with RA, no association between the cathepsins and the severity of the disease, as characterized by DAS28, was observed (p > 0.51).

Conclusions: Although circulating levels of cathepsin S and L were significantly increased in patients with recently diagnosed RA, our data do not support the notion that circulating levels of cathepsins are relevant biomarkers for disease severity.

Ort, förlag, år, upplaga, sidor
2014. Vol. 43, nr 2, s. 371-373
Nationell ämneskategori
Klinisk medicin
Forskningsämne
Hälsa och välfärd
Identifikatorer
URN: urn:nbn:se:du-14212DOI: 10.3109/03009742.2014.882979ISI: 000343002200004PubMedID: 24825074OAI: oai:DiVA.org:du-14212DiVA, id: diva2:723504
Tillgänglig från: 2014-06-10 Skapad: 2014-06-10 Senast uppdaterad: 2017-12-05Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMed

Personposter BETA

Ärnlöv, Johan

Sök vidare i DiVA

Av författaren/redaktören
Ärnlöv, Johan
Av organisationen
Medicinsk vetenskap
I samma tidskrift
Scandinavian Journal of Rheumatology
Klinisk medicin

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 573 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • chicago-author-date
  • chicago-note-bibliography
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf